GHK-Cu Dosage: Doses Studied, Units and Chart
What doses of GHK-Cu have been used in published research, how they convert to syringe units, and what is still unknown.
- Doses studied
- 1 study
- with a stated dose, listed below
- Frequency
- once a week
- as used in studies
- Half-life
- Not found
- No published half-life found (PubMed search, 11 Oct 2026)
- Vial sizes sold
- 50 mg, 100 mg, 200 mg
Doses used in published studies
Each dose below is quoted from a study abstract, strongest design first. Animal doses are labelled and do not translate directly to people. None of them is a recommendation.
| Dose | Frequency and route | Study type | Source |
|---|---|---|---|
| 0.3 or 3 mg/ml | once a week · intra-articular injection · 4 weeks | Animal · rat (not a human result)n = 72 | Journal of orthopaedic research 2015, PMID 25731775 |
Dose to syringe units
For a 50 mg vial mixed with 2 mL of bacteriostatic water (25 mg/mL), on a U-100 syringe. These are reference amounts for the math, not suggested doses.
- 0.5 mg
- 2 u
- 1 mg
- 4 u
- 1.5 mg
- 6 u
- 2 mg
- 8 u
- 2.5 mg
- 10 u
- 3 mg
- 12 u
Before anyone considers it
- GHK-Cu is not FDA approved for any use.
- Products sold as research chemicals are not checked by the FDA for identity, purity or dose.
- Reconstitution math (mg vs mcg, units vs mL) is the most asked question in peptide forums. Check every number twice.
- People who are pregnant, breastfeeding, or have a chronic condition need medical advice first.
Routes in the human studies, and what each stated about amount
In the randomised diabetic-ulcer study of a copper-peptide gel, the abstract describes daily application of a metered dose of drug and gives no mg figure.[14]
In a single-patient cosmetic report, a mixed copper-GHK solution (with four other ingredients) was applied with a microdroplet device once a week for 12 weeks.[15]
Drugs@FDA lists no GHK-Cu product, so there is no labelled strength or schedule for any route.[16]
Animal studies used concentrations, not human-equivalent doses
A rat knee-ligament study compared saline with 0.3 and 3 mg/ml GHK-Cu injected into the joint once a week for 4 weeks, starting in week 2.[4]
In those rats, only the 0.3 mg/ml group had higher graft stiffness than saline at 6 weeks.[4]
A rat wound study applied a topical copper-peptide gel daily for 13 days against a vehicle gel and no treatment.[17]
Common questions
How many units is 1.5 mg of GHK-Cu?
It depends on the water added. A 50 mg vial with 2 mL of water gives 25 mg/mL, so 1.5 mg is 6 units on a U-100 syringe. Use the calculator for other mixes.
Is GHK-Cu FDA approved?
No. GHK-Cu is not FDA approved for any use. The FDA removed it (injectable form) from Category 2 on 15 Apr 2026.
How often is GHK-Cu used in studies?
One single-patient cosmetic report applied a mixed copper-GHK formulation once a week for 12 weeks.[15]
Is there a GHK-Cu dosage reddit consensus?
No. Drugs@FDA lists no GHK-Cu product, and the human data cited here are topical or multi-ingredient.[16]
More on GHK-Cu
Sources
- 1Certain bulk drug substances for use in compounding that may present significant safety risks (Category 2; 'nominated but withdrawn' table, content current as of 22 Apr 2026)U.S. Food and Drug Administration · 2026fda.govAccessed 2 Oct 2026
- 2Metric (SI) Prefixes (NIST Reference on Constants, Units, and Uncertainty)National Institute of Standards and Technology (NIST) · 2025physics.nist.govAccessed 2 Oct 2026
- 3BASAGLAR (insulin glargine) injection, prescribing information (DailyMed)U.S. Food and Drug Administration / DailyMed (Eli Lilly and Company label) · 2026dailymed.nlm.nih.govAccessed 2 Oct 2026
- 4Tripeptide-copper complex GHK-Cu (II) transiently improved healing outcome in a rat model of ACL reconstruction.Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2015PMID 25731775Accessed 2 Oct 2026
- 5PubMed search: ("GHK-Cu"[tiab] OR GHK[tiab] OR "copper tripeptide"[tiab] OR "copper peptide"[tiab] OR "copper peptides"[tiab] OR "glycyl-L-histidyl-L-lysine"[tiab] OR "glycyl-histidyl-lysine"[tiab] OR "Gly-His-Lys"[tiab]) (431 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 6PubMed search: ("GHK-Cu"[tiab] OR GHK[tiab] OR "copper tripeptide"[tiab] OR "copper peptide"[tiab] OR "copper peptides"[tiab] OR "glycyl-L-histidyl-L-lysine"[tiab] OR "glycyl-histidyl-lysine"[tiab] OR "Gly-His-Lys"[tiab]) AND (humans[mh] OR patients[tiab] OR volunteers[tiab]) (150 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 7PubMed search: ("GHK-Cu"[tiab] OR GHK[tiab] OR "copper tripeptide"[tiab] OR "copper peptide"[tiab] OR "copper peptides"[tiab] OR "glycyl-L-histidyl-L-lysine"[tiab] OR "glycyl-histidyl-lysine"[tiab] OR "Gly-His-Lys"[tiab]) AND (randomized[tiab] OR clinical trial[pt] OR split-face[tiab]) (8 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 8PubMed search: ("GHK-Cu"[tiab] OR GHK[tiab] OR "copper tripeptide"[tiab] OR "copper peptide"[tiab] OR "copper peptides"[tiab] OR "glycyl-L-histidyl-L-lysine"[tiab] OR "glycyl-histidyl-lysine"[tiab] OR "Gly-His-Lys"[tiab]) AND (wound[tiab] OR hair[tiab] OR skin[tiab] OR wrinkle*[tiab]) (123 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 9PubMed search: ("GHK-Cu"[tiab] OR GHK[tiab] OR "copper tripeptide"[tiab] OR "copper peptide"[tiab] OR "copper peptides"[tiab] OR "glycyl-L-histidyl-L-lysine"[tiab] OR "glycyl-histidyl-lysine"[tiab] OR "Gly-His-Lys"[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab]) (2 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 10PubMed search: ("GHK-Cu"[tiab] OR GHK[tiab] OR "copper tripeptide"[tiab] OR "copper peptide"[tiab] OR "copper peptides"[tiab] OR "glycyl-L-histidyl-L-lysine"[tiab] OR "glycyl-histidyl-lysine"[tiab] OR "Gly-His-Lys"[tiab]) AND (rat[tiab] OR mice[tiab] OR rats[tiab] OR animal[tiab]) (80 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 11PubMed search: ("GHK-Cu"[tiab] OR "copper tripeptide"[tiab] OR "copper peptide"[tiab] OR "copper peptides"[tiab] OR "glycyl-L-histidyl-L-lysine"[tiab] OR "glycyl-histidyl-lysine"[tiab] OR "Gly-His-Lys"[tiab]) AND (facial[tiab] OR cream[tiab] OR photodamage[tiab] OR volunteers[tiab] OR women[tiab]) (6 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 12PubMed search: ("GHK-Cu"[tiab] OR "copper tripeptide"[tiab] OR "copper peptide"[tiab] OR "copper peptides"[tiab] OR "glycyl-L-histidyl-L-lysine"[tiab] OR "glycyl-histidyl-lysine"[tiab] OR "Gly-His-Lys"[tiab]) AND (hair[tiab] OR alopecia[tiab]) (16 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 13PubMed search: ("GHK-Cu"[tiab] OR "copper tripeptide"[tiab] OR "copper peptide"[tiab] OR "copper peptides"[tiab] OR "glycyl-L-histidyl-L-lysine"[tiab] OR "glycyl-histidyl-lysine"[tiab] OR "Gly-His-Lys"[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab] OR "case report"[pt]) (38 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
- 14Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-l-histidyl-l-lysine copper.Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society · 1994PMID 17147644Accessed 2 Oct 2026
- 15Significant improvement in crow's feet after treatment with Jet-M and a mixed solution of copper-GHK, oligo-hyaluronic acid, rhodiolar extract, tranexamic acid, and β-glucan (GHR formulation).Journal of cosmetic and laser therapy : official publication of the European Society for Laser Dermatology · 2016PMID 27064823Accessed 2 Oct 2026
- 16Drugs@FDA (openFDA) search: active ingredient "GHK-Cu"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
- 17The effect of topical tripeptide-copper complex on healing of ischemic open wounds.Veterinary surgery : VS · 2003PMID 14648529Accessed 2 Oct 2026
Found an error? Report a correction.